Tiger Brokers

Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million

Reuters
5 hours ago
Dermata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million
  • Dermata filed a Form 8-K reporting full-year 2025 results, including a net loss of USD 7.6 million.
  • Research and development expense fell 64.27% to USD 2.9 million, primarily due to lower clinical costs after completion of the STAR-1 acne study in Q2 2025.
  • Selling, general and administrative expense rose 12.42% to USD 4.8 million, driven mainly by USD 0.7 million in marketing expense.
  • Cash and cash equivalents were USD 7.5 million as of Dec. 31, 2025, and the company said its cash resources are expected to fund operations into Q1 2027.
  • Management said Dermata is pivoting to direct-to-consumer skincare under the Tome brand, with a first product launch targeted for mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012991), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10